中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

23 records (took 0.013 seconds)

    ANTI-PRLR ANTIBODIES AND USES THEREOF
    1.
    发明申请
    ANTI-PRLR ANTIBODIES AND USES THEREOF 审中-公开
    抗PRLR抗体及其用途

    公开(公告)号：WO2015026907A1

    公开(公告)日：2015-02-26

    申请号：PCT/US2014/051831

    申请日：2014-08-20

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： PAPADOPOULOS, Nicholas ,  THURSTON, Gavin ,  KIRSHNER, Jessica ,  KELLY, Marcus ,  NITTOLI, Thomas ,  DELFINO, Frank

    IPC: C07K16/28 ,  A61K47/48 ,  A61P35/00

    CPC classification number: C07K16/2866 ,  A61K31/537 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

    Abstract: The present disclosure provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the disclosure bind human PRLR with high affinity. In certain embodiments, the disclosure includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the disclosure includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the disclosure may be fully human antibodies. The disclosure includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the disclosure are useful for the treatment of various cancers as well as other PRLR-related disorders. The present disclosure also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.

    Abstract translation: 本公开提供了结合催乳素受体（PRLR）的抗体及其使用方法。 根据某些实施方案，本公开的抗体以高亲和力结合人PRLR。 在某些实施方案中，本公开包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中，本公开包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 本公开的抗体可以是完全人抗体。 本公开内容包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本公开的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本公开还包括抗体药物缀合物，其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段，其中抗体或其抗原结合片段与细胞毒性剂缀合。

    DIELS-ALDER CONJUGATION METHODS
    10.
    发明申请
    DIELS-ALDER CONJUGATION METHODS 审中-公开

    公开(公告)号：WO2021211984A1

    公开(公告)日：2021-10-21

    申请号：PCT/US2021/027707

    申请日：2021-04-16

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： NITTOLI, Thomas

    IPC: A61K47/68

    Abstract: Described herein are protein-payload conjugates and compositions thereof that are useful, for example, for target-specific delivery of therapeutic and/or imaging agent moieties. In certain embodiments, provided are specific and efficient methods for producing protein-payload constructs (e.g., antibody-drug conjugates) utilizing a combination of transglutaminase and Diels-Alder techniques. Antibody-drug conjugates and compositions which comprise glutaminyl-modified antibodies, Diels-Alder adducts, and reactive payloads and are provided.

Patent Agency Ranking